Gilead Signs US$1.53 B Deal with Scholar Rock to Strengthen its Fibrotic Diseases Pipeline
By Sharath Chandra Nakka & Michelle Liu
Pharma Deals Review: Vol 2019 Issue 1 (Table of Contents)
Published: 8 Jan-2019
DOI: 10.3833/pdr.v2019.i1.2391 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
With a focus on strengthening its fibrotic diseases pipeline, Gilead has agreed to collaborate with Scholar Rock to gain exclusive developmental and commercialisation rights to its transforming growth factor beta programme candidates for the treatment of fibrotic diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS